Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ: BNTX )

113.96 +1.53 (+1.36%)
Streaming Delayed Price Updated: 3:54 PM EST, Jan 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
65 66 Next >
US Schedules Covid-19 Vaccines For Children Below Five Years
Via Benzinga
HC Wainwright Says Non-mRNA COVID-19 Option Underappreciated
HC Wainwright says safety concerns were noted for Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine, but the strength of data showed that benefit outweighs risks. 
Via Benzinga
What's Next For Novavax Stock As COVID Vaccine Clears Key Hurdle In US
After last week's scare stirred by the release of the Food And Drug Administration's briefing documents, Novavax (NASDAQ: NVAX) can now heave a sigh of relief. 
Via Benzinga
COVID-19 Vaccine Patent Waiver Expected Soon, Says WTO Head: Reuters
Via Benzinga
Pfizer To Boost Production Of Oral COVID-19 Pill With $120M Michigan Investment
Pfizer, Inc. (NYSE: PFE) is upping its commitment to manufacture its oral COVID-19 pill Paxlovid in the United States. 
Via Benzinga
Short Volatility Alert: BioNTech SE
On Friday, shares of BioNTech SE (NASDAQ: BNTX) experienced volatile short activity. After the activity, the stock price went down -0.42% to $157.70. The overall sentiment... 
Via Benzinga
Early Data Shows BioNTech's Personalized Therapy Safe In Pancreatic Cancer Patients
Via Benzinga
6 Biotech Stocks to Buy Now Ahead of These June Catalysts
These biotech stocks face some key make-or-break events in June that could have big implication for their futures. 
Via InvestorPlace
Morning Brief: Top Financial Stories Dominating on Thursday, June 2
Reuters 
Via Benzinga
Why The FDA Isn't The Battleground For Pfizer's, Moderna's Pediatric Covid Shots
FDA's OK is just step one. Then Pfizer and Moderna need to get parents on board. 
Via Investor's Business Daily
Pfizer Seeks FDA Approval For Three Covid Vaccine Doses For Children Below Five
Via Benzinga
Jim Cramer Shares His Opinion On Roblox, Century Aluminum And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he can’t recommend Roblox Corp (NASDAQ: RBLX) as it is not making money. 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
CanSino's Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late?
Key Takeaways: CanSino’s Covid-19 vaccine Convidecia will be admitted to the global Covax program following its approval by the WHO The approval could have limited... 
Via Benzinga
7 of the Best Cheap Stocks to Buy for the Second Half of 2022
These are the best cheap stocks to invest in now. They all offer compelling buying opportunities in today's volatile market. 
Via InvestorPlace
Pfizer, BioNTech Say Three-Dose Covid Vaccine Is 80% Effective In Children Under 5
Pfizer tested a three-dose vaccine in nearly 1,700 children. 
Via Investor's Business Daily
Morning Brief: Top Financial Stories Dominating on Monday, May 23
CNBC US Announces Asia Economic Deal To Strengthen Foothold, Check China 
Via Benzinga
European Regulator Approves AstraZeneca's COVID-19 shot As Booster
Via Benzinga
Pfizer-BioNTech's Third COVID-19 Vaccine Shot Shows 80% Efficacy In Youngest Children
Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine 
Via Benzinga
Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
From Pfizer Inc.
Via Business Wire
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support. 
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Friday, May 20
Reuters 
Via Benzinga
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
CDC Recommends Pfizer/BioNTech COVID-19 Booster Shots For Kids Aged 5-11 Years
Via Benzinga
Cramer Shares His Thoughts On BioNTech, Vertex Energy And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Veru Inc. (NASDAQ: VERU) is "up a great deal … we caught it much lower." 
Via Benzinga
The Daily Biotech Pulse: Pfizer/BioNTech's COVID-19 Booster For Kids, Moderna Starts First African Trial Of mRNA HIV Vaccine, Tonix Extends COVID-19 Antiviral Research Pact
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
FDA Gives Green Signal To Pfizer/BioNTech's COVID-19 Booster For Kids 5-11 Years
Via Benzinga
Pfizer Retakes A Key Line — And Drags BioNTech, Moderna With It
The FDA decision also prodded BioNTech and Moderna stocks higher. 
Via Investor's Business Daily
Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
From Pfizer Inc.
Via Business Wire
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
65 66 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.